Nurix Therapeutics (NRIX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Nurix will report Q1 2026 results before the market opens on April 14, with analysts forecasting a loss of ($0.76) per share and revenue of about $14.25M; a related conference call is scheduled for April 17 at 4:00 PM ET.
• Analyst sentiment is largely positive (average rating "Moderate Buy") with a consensus price target of $30.54, compared with the recent share price around $15.79
• Insider selling has occurred: two executives recently sold shares (reducing their stakes) and insiders now own about 7.40% of the company.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) is projected to issue its Q1 2026 results before the market opens on Tuesday, April 14th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $14.2530 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, April 17, 2026 at 4:00 PM ET.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.02. The business had revenue of $13.58 million during the quarter, compared to the consensus estimate of $13.41 million. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Trading Up 1.8%

Shares of NASDAQ:NRIX opened at $15.79 on Tuesday. The company has a market capitalization of $1.63 billion, a PE ratio of -5.19 and a beta of 1.97. Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $22.50. The firm has a 50 day simple moving average of $15.83 and a 200-day simple moving average of $15.16.

Analysts Set New Price Targets

NRIX has been the subject of several recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Nurix Therapeutics in a research report on Thursday, January 22nd. Stifel Nicolaus lifted their target price on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, January 29th. Mizuho lifted their target price on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the company an "outperform" rating in a report on Wednesday, December 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $26.00 target price on shares of Nurix Therapeutics in a report on Thursday, January 29th. Finally, Wells Fargo & Company cut their target price on shares of Nurix Therapeutics from $30.00 to $29.00 and set an "overweight" rating on the stock in a report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $30.54.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,895 shares of the business's stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $81,257.00. Following the transaction, the insider directly owned 83,672 shares of the company's stock, valued at approximately $1,388,955.20. The trade was a 5.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 3,661 shares of the business's stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the transaction, the chief financial officer directly owned 45,427 shares in the company, valued at $754,088.20. This represents a 7.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 7.40% of the company's stock.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System increased its stake in Nurix Therapeutics by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 68,019 shares of the company's stock valued at $1,290,000 after buying an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management acquired a new position in Nurix Therapeutics in the 4th quarter valued at $31,000. Royal Bank of Canada increased its stake in Nurix Therapeutics by 17.6% in the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company's stock valued at $206,000 after buying an additional 1,623 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Nurix Therapeutics in the 4th quarter valued at $33,000. Finally, Russell Investments Group Ltd. increased its stake in Nurix Therapeutics by 5.0% in the 4th quarter. Russell Investments Group Ltd. now owns 63,482 shares of the company's stock valued at $1,204,000 after buying an additional 3,046 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company's pipeline includes multiple programs in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.